Nivolumab
Showing 1 - 25 of 1,700
Melanoma Trial in Rotterdam (Nivolumab)
Recruiting
- Melanoma
- Nivolumab
-
Rotterdam, Pending, NetherlandsErasmus MC
Oct 30, 2023
Recurrent Glioblastoma Trial in Brussels (Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV,
Not yet recruiting
- Recurrent Glioblastoma
- Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
- +2 more
-
Brussels, BelgiumUZ Brussel
Oct 23, 2023
Melanoma Trial (ABP 206, FDA-licensed Nivolumab, EU-authorized Nivolumab)
Not yet recruiting
- Melanoma
- ABP 206
- +2 more
- (no location specified)
Jun 8, 2023
Tumors, Carcinoma, Squamous, Antineoplastic Agents Trial (Nivolumab Injection [Opdivo])
Not yet recruiting
- Neoplasms
- +2 more
- Nivolumab Injection [Opdivo]
- (no location specified)
Jul 19, 2023
Melanoma Trial (ABP 206, Nivolumab)
Not yet recruiting
- Melanoma
- ABP 206
- Nivolumab
- (no location specified)
Sep 20, 2023
Acute Anterior ST Segment Elevation Myocardial Infarction Trial (Nivolumab, Placebo)
Not yet recruiting
- Acute Anterior ST Segment Elevation Myocardial Infarction
- Nivolumab
- Placebo
- (no location specified)
Jun 6, 2023
Merkel Cell Carcinoma Trial in Wollstonecraft (Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination)
Not yet recruiting
- Merkel Cell Carcinoma
- Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
-
Wollstonecraft, New South Wales, AustraliaMelanoma Institute Australia
Nov 21, 2023
Renal Cell Carcinoma Trial in Houston (Tivozanib, Nivolumab)
Not yet recruiting
- Renal Cell Carcinoma
- Tivozanib
- Nivolumab
-
Houston, TexasM D Anderson Cancer Center
Sep 19, 2023
Melanoma Stage IV, Melanoma Stage III, Immunetherapy Trial (nivolumab)
Not yet recruiting
- Melanoma Stage IV
- +3 more
- nivolumab
- (no location specified)
Dec 14, 2022
Melanoma (Skin) Trial in Houston (BMS-986213 (Relatlimab-Nivolumab FDC), Nivolumab, Relatlimab)
Not yet recruiting
- Melanoma (Skin)
- BMS-986213 (Relatlimab-Nivolumab FDC)
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 1, 2023
Cutaneous Squamous Cell Carcinoma Trial in Amsterdam (Nivolumab, Ipilimumab)
Recruiting
- Cutaneous Squamous Cell Carcinoma
- Nivolumab
- Ipilimumab
-
Amsterdam, Noord Holland, NetherlandsNKI-AVL
Oct 24, 2022
Advanced Glioblastoma, Metastatic Melanoma in the CNS, MGMT-Unmethylated Glioblastoma Trial in Ramat Gan (Crizanlizumab-Tmca 10
Not yet recruiting
- Advanced Glioblastoma
- +2 more
- Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
- Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
-
Ramat Gan, IsraelSheba medical center
Jun 11, 2023
Squamous Cell Carcinoma of Head and Neck Trial (Combination 5-azacytidine and nivolumab, 5-azacytidine, Nivolumab)
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
- Combination 5-azacytidine and nivolumab
- +2 more
- (no location specified)
Dec 7, 2022
RCC, Renal Cell Carcinoma Trial in Dallas (Cabozantinib 80 MG, Cabozantinib 40Mg Tab, Nivolumab)
Not yet recruiting
- RCC
- Renal Cell Carcinoma
- Cabozantinib 80 MG
- +2 more
-
Dallas, TexasUT Southwestern Medical Center
Jul 3, 2023
Immune Suppression, Gastric Cancer Trial in Hangzhou (nivolumab combined with SOX)
Recruiting
- Immune Suppression
- Gastric Cancer
- nivolumab combined with SOX
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Feb 11, 2023
Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)
Recruiting
- Melanoma
- Metastatic Melanoma
- CDX-301
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 12, 2023
Glioblastoma, GBM, Glioblastoma Multiforme Trial in Los Angeles, Boston, New York (Nivolumab-Placebo, Nivolumab,
Recruiting
- Glioblastoma
- +3 more
- Nivolumab-Placebo
- +4 more
-
Los Angeles, California
- +3 more
Jan 16, 2023
Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,
Recruiting
- Metastatic Gastric Cancer
- +2 more
- Nivolumab
- +2 more
-
New York, New YorkBureau for Cancer Research
May 10, 2023
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial
Not yet recruiting
- Metastatic Nasopharyngeal Carcinoma
- +2 more
- Nivolumab
- +5 more
- (no location specified)
Aug 21, 2023
Metastatic Renal Cell Carcinoma Trial in Italy (Axitinib, Nivolumab)
Not yet recruiting
- Metastatic Renal Cell Carcinoma
- Axitinib
- Nivolumab
-
Brescia, Italy
- +22 more
Apr 19, 2023
Metastatic Renal Cell Carcinoma Trial in Cleveland (Nivolumab, Ipilimumab)
Active, not recruiting
- Metastatic Renal Cell Carcinoma
- Nivolumab
- Ipilimumab
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 25, 2023
Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer Trial in Israel, United States (CM-24 and Nivolumab - Dose
Recruiting
- Solid Tumor
- +6 more
- CM-24 and Nivolumab - Dose Escalation
- +4 more
-
Scottsdale, Arizona
- +10 more
Jan 17, 2023
Safety Issues, Efficacy, Self Trial in Monterrey (low dose nivolumab in combination with AVD)
Recruiting
- Safety Issues
- Efficacy, Self
- low dose nivolumab in combination with AVD
-
Monterrey, Nuevo Leon, MexicoHospital Universitario Dr Jose Eleuterio Gonzalez
Mar 6, 2023